AAPL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
Apple Inc. · Technology
$308.63
+5.6% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
AAPL has more upside to fair value
(+5.6%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
PFE |
| Current Price |
$308.63 |
$25.22 |
| Fair Value Estimate |
$325.93 |
$25.92 |
| Upside to Fair Value |
+5.6%
|
+2.8%
|
| Market Cap |
$4,533.0B |
$143.7B |
| Forward P/E |
37.2x
|
19.2x
|
| EV / EBITDA |
28.6x
|
12.3x
|
| Price / Sales |
10.0x
|
2.3x
|
| Price / FCF |
35.1x
|
15.2x
|
| Revenue Growth YoY |
+16.6%
|
+5.4%
|
| Gross Margin |
47.9%
|
69.3%
|
| Operating Margin |
32.6%
|
23.4%
|
| Return on Equity |
146.7%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.85%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services, with a durable competitive moat driven by its integrated ecosystem of devices, operating systems, and services. The company benefits from strong brand loyalty, high margins with a gross margin of 47.9%, and consistent earnings growth, including a 19.4% increase in earnings in the most recent q…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
AAPL |
PFE |
| Zone Low |
$244.45 |
$19.44 |
| Zone High |
$277.04 |
$22.03 |
| In Buy Zone? |
No
|
No
|